Company intelligence / Profile preview
Novaremed
Basel, Basel-Stadt, Switzerlandnovaremed.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company’s lead candidate, NRD.E1, an orally active non-opioid small molecule with a novel mechanism of action, is currently in an NIH-sponsored Phase 2b clinical trial for painful diabetic peripheral neuropathy. MP‑101 has completed Phase 2 studies for prevention of chemotherapy-induced peripheral neuropathy. MP‑103 remains at the preclinical stage targeting CIPN and other forms of peripheral neuropathy. No pivotal or registration-enabling data have been reported as of June 2025.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Interested in pharmaceutical partnerships (none specified)
Beyond the preview
Go deeper on Novaremed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novaremed.